In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts,...
Ambio Life Sciences, a company known for its physician-led ibogaine therapy programmes, has been thrust into the global spotlight with the release of In Waves and...
A newly published systematic review titled on psilocybin’s effects on obsessive‑compulsive behaviours provides an up-to-date synthesis of research into the compound’s potential for treating OCD and...
Dr. Celia Morgan is one of the UK’s leading figures in ketamine and psychedelic research, especially in the domain of addiction and mental health.
For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment.
On Friday, the Royal College of Psychiatrists has published a new report assessing the safety and efficacy of psychedelics and related substances as treatments for mental...
Psychedelic medicine took a major step forward this month as JAMA published results from the first randomized, placebo-controlled trial of LSD for anxiety.
The past year featured some of Britain’s most significant landmarks in advancing access to psychedelic medicine.
A trend towards the legalization of psychedelic substances for medical use continues across the English-speaking world.
Lykos Therapeutics, formerly MAPS Public Benefit Corporation, has announced it has received FDA acceptance and priority review for a New Drug Application (NDA) concerning its MDMA-assisted...
